P865: TECLISTAMAB IN COMBINATION WITH LENALIDOMIDE IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA IN THE PHASE 1B MULTICOHORT MAJESTEC-2 STUDY
Carlyn Tan(United States Fish and Wildlife Service), Cyrille Touzeau(Centre National de la Recherche Scientifique), Andrew J. Cowan(University of Washington Medical Center), Wojciech Janowski, Emma Searle(University of Manchester), Deeksha Vishwamitra(Janssen (United States)), Manisha Bhutani(Carolinas Healthcare System), Jesús G. Berdeja(Tennessee Oncology), Noa Biran(Hackensack University Medical Center), Arnob Banerjee(Johnson & Johnson (United States)), Zhuolu Niu, Rakesh Popat(University College London Hospitals NHS Foundation Trust), Aurore Perrot(Institut universitaire du cancer de Toulouse Oncopole), Sandy W. Wong(UCSF Helen Diller Family Comprehensive Cancer Center), Hang Quach(The University of Melbourne), Mark A. Schroeder(MACOM (United States)), Lingling Chen(Second Affiliated Hospital of Nanjing Medical University), Yue Guo(Janssen (United States)), Julie S. Larsen(Janssen (United States)), Sébastien Anguille(Antwerp University Hospital), Jeffrey Matous(Colorado Blood Cancer Institute), Kevin Boyd(Royal Marsden Hospital)
Cited by 7
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k